
MIDAS Webinar: Introduction to infectious disease modeling and the need for diverse perspectives
Join us for the next MIDAS Webinar featuring MIDAS member Dr. Caroline Buckee!
For general guidance and information about the global COVID-19 situation, follow information by the World Health Organization.
For guidance on the U.S. situation, see the U.S. CDC COVID-19 website.
For journalists and the general public, see the Software Catalog for a list of dashboards and visualizations to follow the COVID-19 pandemic.
For researchers and others interested in COVID-19 data and parameter estimates, see the Data and Information section.
For questions or ideas regarding COVID-19 modeling research, contact questions@midasnetwork.us.
Join us for the next MIDAS Webinar featuring MIDAS member Dr. Caroline Buckee!
Join a large community of scientists and engineers from academia and industry, collaborating virtually in a community forum to explore how we might converge to build actionable predictive intelligence for pandemic prevention (PIPP).
MIDAS member and IDASTP Director Jacobus de Roode will moderate this panel exploring career pathways in the field of infectious disease across scales approach.
The 2021 University of Washington Summer Institute courses are again offered online this year. Many MIDAS members are instructors.
Join us for the next MIDAS Webinar featuring MIDAS member Dr. Caroline Buckee!
Join a large community of scientists and engineers from academia and industry, collaborating virtually in a community forum to explore how we might converge to build actionable predictive intelligence for pandemic prevention (PIPP).
MIDAS member and IDASTP Director Jacobus de Roode will moderate this panel exploring career pathways in the field of infectious disease across scales approach.
Join us for the next MIDAS Webinar featuring MIDAS member Dr. Caroline Buckee!
Join a large community of scientists and engineers from academia and industry, collaborating virtually in a community forum to explore how we might converge to build actionable predictive intelligence for pandemic prevention (PIPP).
MIDAS member and IDASTP Director Jacobus de Roode will moderate this panel exploring career pathways in the field of infectious disease across scales approach.
The 2021 University of Washington Summer Institute courses are again offered online this year. Many MIDAS members are instructors.
Join us for the next MIDAS Webinar featuring MIDAS member Dr. Caroline Buckee!
Join a large community of scientists and engineers from academia and industry, collaborating virtually in a community forum to explore how we might converge to build actionable predictive intelligence for pandemic prevention (PIPP).
MIDAS member and IDASTP Director Jacobus de Roode will moderate this panel exploring career pathways in the field of infectious disease across scales approach.
name | value | country | lower bound | upper bound | age range | start date | end date | publication date | source |
---|---|---|---|---|---|---|---|---|---|
Basic reproduction number | 2.36 | United States | Unspecified | Unspecified | Unspecified | 2020-03-02 | 2020-03-25 | 2020-05-18 | Turk PJ, et al. |
Basic reproduction number | 1.79 | United States | Unspecified | Unspecified | Unspecified | 2020-03-02 | 2020-03-25 | 2020-05-18 | Turk PJ, et al. |
Basic reproduction number | 1.33 | United States | Unspecified | Unspecified | Unspecified | 2020-03-26 | 2020-04-07 | 2020-05-18 | Turk PJ, et al. |
Basic reproduction number | 1.34 | United States | Unspecified | Unspecified | Unspecified | 2020-03-26 | 2020-04-07 | 2020-05-18 | Turk PJ, et al. |
Doubling time | 2.56 | United States | 2.11 | 3.25 | Unspecified | 2020-03-02 | 2020-03-25 | 2020-05-18 | Turk PJ, et al. |
Doubling time | 2.94 | United States | 2.33 | 4 | Unspecified | 2020-03-02 | 2020-03-25 | 2020-05-18 | Turk PJ, et al. |
Doubling time | 4.7 | United States | 3.77 | 6.22 | Unspecified | 2020-03-02 | 2020-04-07 | 2020-05-18 | Turk PJ, et al. |
Doubling time | 4.01 | United States | 3.43 | 4.83 | Unspecified | 2020-03-02 | 2020-04-07 | 2020-05-18 | Turk PJ, et al. |
Growth rate | 0.168 | United States | 0.159 | 0.178 | Unspecified | 2020-03-21 | 2020-04-04 | 2020-05-15 | Chen D, et al. |
Growth rate parameter | 0.3 | Peru | 0.3 | 0.5 | Unspecified | 2020-02-29 | 2020-03-15 | 2020-05-12 | Munayco CV, et al. |
Basic reproduction number | 2.3 | Peru | 2 | 2.5 | Unspecified | 2020-02-29 | 2020-03-15 | 2020-05-12 | Munayco CV, et al. |
Effective reproduction number | 1.85 | Italy | 0.6 | 2.3 | Unspecified | 2020-02-26 | 2020-04-20 | 2020-05-10 | Chinatalapudi N, et al. |
Effective reproduction number | 2.49 | Italy | 1.1 | 4.5 | Unspecified | 2020-02-26 | 2020-04-20 | 2020-05-10 | Chinatalapudi N, et al. |
Effective reproduction number | 2.16 | Italy | 1 | 4 | Unspecified | 2020-02-26 | 2020-04-20 | 2020-05-10 | Chinatalapudi N, et al. |
Effective reproduction number | 1.51 | Italy | 0.75 | 2.75 | Unspecified | 2020-02-26 | 2020-04-20 | 2020-05-10 | Chinatalapudi N, et al. |
Effective reproduction number | 1.14 | Italy | 1 | 1.6 | Unspecified | 2020-02-26 | 2020-04-20 | 2020-05-10 | Chinatalapudi N, et al. |
Effective reproduction number | 1.79 | Italy | 1 | 3.5 | Unspecified | 2020-02-26 | 2020-04-20 | 2020-05-10 | Chinatalapudi N, et al. |
Effective reproduction number | 2.9 | Spain | 2.67 | 3.14 | Unspecified | 2020-02-26 | 2020-03-06 | 2020-04-30 | Caicedo-Ochoa Y, et al. |
Effective reproduction number | 2.83 | Italy | 2.7 | 2.96 | Unspecified | 2020-02-22 | 2020-03-02 | 2020-04-30 | Caicedo-Ochoa Y, et al. |
Effective reproduction number | 3.95 | Ecuador | 3.7 | 4.21 | Unspecified | 2020-03-14 | 2020-03-24 | 2020-04-30 | Caicedo-Ochoa Y, et al. |
Effective reproduction number | 3.67 | Panama | 3.25 | 4.13 | Unspecified | 2020-03-13 | 2020-03-23 | 2020-04-30 | Caicedo-Ochoa Y, et al. |
Effective reproduction number | 2.91 | Brazil | 2.6 | 3.23 | Unspecified | 2020-03-09 | 2020-03-19 | 2020-04-30 | Caicedo-Ochoa Y, et al. |
Effective reproduction number | 2.67 | Chile | 2.45 | 2.89 | Unspecified | 2020-03-15 | 2020-03-25 | 2020-04-30 | Caicedo-Ochoa Y, et al. |
Effective reproduction number | 2.67 | Colombia | 2.38 | 2.98 | Unspecified | 2020-03-15 | 2020-03-25 | 2020-04-30 | Caicedo-Ochoa Y, et al. |
Effective reproduction number | 2.36 | Peru | 2.11 | 2.63 | Unspecified | 2020-03-13 | 2020-03-23 | 2020-04-30 | Caicedo-Ochoa Y, et al. |
Effective reproduction number | 2.42 | Mexico | 2.14 | 2.72 | Unspecified | 2020-03-12 | 2020-03-22 | 2020-04-30 | Caicedo-Ochoa Y, et al. |
Basic reproduction number | 3.6 | Italy | 3.49 | 3.84 | Unspecified | 2020-02-22 | 2020-03-08 | 2020-04-23 | Gatto M, et al. |
Proportion of hospitalized cases on mechanical ventilation | 0.202380952 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-01-30 | 2020-04-10 | Xie , et al. |
Proportion of hospitalized cases on extracorporeal membrane oxygenation (ecmo) | 0.011904762 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-01-30 | 2020-04-10 | Xie , et al. |
Effective reproduction number | 3.28 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-12 | 2020-04-10 | Maier BF, et al. |
Effective reproduction number | 1.93 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-12 | 2020-04-10 | Maier BF, et al. |
Effective reproduction number | 3.02 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-12 | 2020-04-10 | Maier BF, et al. |
Effective reproduction number | 2.41 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-12 | 2020-04-10 | Maier BF, et al. |
Effective reproduction number | 3.1 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-12 | 2020-04-10 | Maier BF, et al. |
Effective reproduction number | 3.28 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-12 | 2020-04-10 | Maier BF, et al. |
Effective reproduction number | 1.7 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-12 | 2020-04-10 | Maier BF, et al. |
Effective reproduction number | 3.46 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-12 | 2020-04-10 | Maier BF, et al. |
Effective reproduction number | 1.75 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-12 | 2020-04-10 | Maier BF, et al. |
Effective reproduction number | 1.36 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-12 | 2020-04-10 | Maier BF, et al. |
Secondary attack rate | 77.00% | Canada | 63.00% | 83.00% | 5-14 | Unspecified | Unspecified | 2020-04-09 | Tuite AR, et al. |
Secondary attack rate | 63.00% | Canada | 48.00% | 71.00% | 15-49 | Unspecified | Unspecified | 2020-04-09 | Tuite AR, et al. |
Secondary attack rate | 50.00% | Canada | 37.00% | 58.00% | 0-5 | Unspecified | Unspecified | 2020-04-09 | Tuite AR, et al. |
Secondary attack rate | 47.00% | Canada | 34.00% | 55.00% | 50-69 | Unspecified | Unspecified | 2020-04-09 | Tuite AR, et al. |
Secondary attack rate | 30.00% | Canada | 21.00% | 36.00% | 70-130 | Unspecified | Unspecified | 2020-04-09 | Tuite AR, et al. |
Incubation period | 4.2 | China | 3.5 | 5.1 | Unspecified | 2020-01-15 | 2020-01-20 | 2020-04-08 | Sanche S, et al. |
Basic reproduction number | 5.7 | China | 3.8 | 8.9 | Unspecified | 2020-01-15 | 2020-01-20 | 2020-04-08 | Sanche S, et al. |
Growth rate | 0.27 | China | 0.21 | 0.29 | Unspecified | 2020-01-15 | 2020-01-20 | 2020-04-08 | Sanche S, et al. |
Doubling time | 2.7 | China | 2.3 | 3.3 | Unspecified | 2020-01-15 | 2020-01-20 | 2020-04-08 | Sanche S, et al. |
Time from symptom onset to hospitalization | 5.5 | China | 4.6 | 6.6 | Unspecified | Unspecified | 2020-01-18 | 2020-04-08 | Sanche S, et al. |
Time from symptom onset to hospitalization | 1.5 | China | 1.2 | 1.9 | Unspecified | 2020-01-19 | 2020-01-30 | 2020-04-08 | Sanche S, et al. |
Time from hospitalization to recovery | 11.5 | China | 9 | 17.3 | Unspecified | 2020-01-15 | 2020-01-20 | 2020-04-08 | Sanche S, et al. |
Time from hospitalization to death | 11.2 | China | 8.7 | 14.9 | Unspecified | 2020-01-15 | 2020-01-20 | 2020-04-08 | Sanche S, et al. |
Time from symptom onset to death | 16.1 | China | 13.1 | 20.2 | Unspecified | 2020-01-15 | 2020-01-20 | 2020-04-08 | Sanche S, et al. |
Proportion of hospitalized cases admitted to icu | 0.062264 | China | Unspecified | Unspecified | Unspecified | 2019-11-21 | 2020-01-31 | 2020-04-08 | Liang W, et al. |
Proportion of hospitalized cases on mechanical ventilation | 0.031447 | China | Unspecified | Unspecified | Unspecified | 2019-11-21 | 2020-01-31 | 2020-04-08 | Liang W, et al. |
Proportion of hospitalized cases that die | 0.031447 | China | Unspecified | Unspecified | Unspecified | 2019-11-21 | 2020-01-31 | 2020-04-08 | Liang W, et al. |
Time from symptom onset to hospitalization | 5.7 | China | Unspecified | Unspecified | Unspecified | 2019-11-21 | 2020-01-31 | 2020-04-08 | Liang W, et al. |
Time from symptom onset to hospitalization | 4.5 | China | Unspecified | Unspecified | Unspecified | 2019-11-21 | 2020-01-31 | 2020-04-08 | Liang W, et al. |
Proportion of icu patients that die | 0.26 | Italy | 0.23 | 0.28 | Unspecified | 2020-02-20 | 2020-03-18 | 2020-04-06 | Grasselli G, et al. |
Proportion of icu cases on mechanical ventilation | 0.88 | Italy | 0.87 | 0.9 | Unspecified | 2020-02-20 | 2020-03-18 | 2020-04-06 | Grasselli G, et al. |
Proportion of icu cases on extracorporeal membrane oxygenation (ecmo) | 0.01 | Italy | 0.003 | 0.02 | Unspecified | 2020-02-20 | 2020-03-18 | 2020-04-06 | Grasselli G, et al. |
Duration of icu stay | 9 | Italy | 6 | 13 | Unspecified | 2020-02-20 | 2020-03-18 | 2020-04-06 | Grasselli G, et al. |
Time from symptom onset to hospitalization | 5 | China | 3 | 12 | 0-18 | 2020-01-31 | 2020-02-16 | 2020-04-06 | Han Y, et al. |
Proportion of hospitalized cases treated with antivirals | 0 | China | Unspecified | Unspecified | 0-18 | 2020-01-31 | 2020-02-16 | 2020-04-06 | Han Y, et al. |
Proportion of hospitalized cases that die | 0 | China | Unspecified | Unspecified | 0-18 | 2020-01-31 | 2020-02-16 | 2020-04-06 | Han Y, et al. |
Proportion of hospitalized cases admitted to icu | 0 | China | Unspecified | Unspecified | 0-18 | 2020-01-31 | 2020-02-16 | 2020-04-06 | Han Y, et al. |
Proportion of hospitalized cases on mechanical ventilation | 0 | China | Unspecified | Unspecified | 0-18 | 2020-01-31 | 2020-02-16 | 2020-04-06 | Han Y, et al. |
Proportion of hospitalized cases on extracorporeal membrane oxygenation (ecmo) | 0 | China | Unspecified | Unspecified | 0-18 | 2020-01-31 | 2020-02-16 | 2020-04-06 | Han Y, et al. |
Time from symptom onset to hospitalization | 3.8 | China | 0 | 12 | Unspecified | 2020-12-24 | 2020-02-17 | 2020-04-02 | Zhang J, et al. |
Time from symptom onset to hospitalization | 4.4 | China | 0 | 14 | Unspecified | 2020-12-24 | 2020-01-27 | 2020-04-02 | Zhang J, et al. |
Time from symptom onset to hospitalization | 2.6 | China | 0 | 9 | Unspecified | 2020-01-28 | 2020-02-17 | 2020-04-02 | Zhang J, et al. |
Incubation period | 5.2 | China | 1.8 | 12.4 | Unspecified | 2020-12-24 | 2020-02-14 | 2020-04-02 | Zhang J, et al. |
Time from symptom onset to reporting | 7.4 | China | 1 | 18 | Unspecified | 2020-12-24 | 2020-02-17 | 2020-04-02 | Zhang J, et al. |
Time from symptom onset to reporting | 8.9 | China | 2 | 19.8 | Unspecified | 2020-12-24 | 2020-01-27 | 2020-04-02 | Zhang J, et al. |
Time from symptom onset to reporting | 5.4 | China | 1 | 12 | Unspecified | 2020-01-28 | 2020-02-17 | 2020-04-02 | Zhang J, et al. |
Serial interval | 5.1 | China | 1.3 | 11.6 | Unspecified | 2020-12-24 | 2020-02-17 | 2020-04-02 | Zhang J, et al. |
Proportion of hospitalized cases treated with antivirals | 0.235294118 | Singapore | Unspecified | Unspecified | Unspecified | 2020-01-18 | 2020-02-10 | 2020-03-28 | Pung R, et al. |
Proportion of hospitalized cases admitted to icu | 0.117647059 | Singapore | Unspecified | Unspecified | Unspecified | 2020-01-18 | 2020-02-10 | 2020-03-28 | Pung R, et al. |
Proportion of hospitalized cases that die | 0 | Singapore | Unspecified | Unspecified | Unspecified | 2020-01-18 | 2020-02-10 | 2020-03-28 | Pung R, et al. |
Time from symptom onset to hospitalization | 4 | Singapore | 3 | 9 | Unspecified | 2020-01-18 | 2020-02-10 | 2020-03-28 | Pung R, et al. |
Proportion of hospitalized cases that die | 0 | China | Unspecified | Unspecified | 16-130 | 2020-02-07 | 2020-02-12 | 2020-03-27 | Wang , et al. |
Time from symptom onset to hospitalization | 10 | China | 7 | 14 | 16-130 | 2020-02-07 | 2020-02-12 | 2020-03-27 | Wang , et al. |
Proportion of hospitalized cases treated with antibiotics | 1 | China | Unspecified | Unspecified | Unspecified | 2020-01-07 | 2020-02-11 | 2020-03-24 | Chu , et al. |
Proportion of hospitalized cases treated with antivirals | 0.574074 | China | Unspecified | Unspecified | Unspecified | 2020-01-07 | 2020-02-11 | 2020-03-24 | Chu , et al. |
Proportion of hospitalized cases that die | 0.018519 | China | Unspecified | Unspecified | Unspecified | 2020-01-07 | 2020-02-11 | 2020-03-24 | Chu , et al. |
Proportion of hospitalized cases on mechanical ventilation | 0.714285714 | United States | Unspecified | Unspecified | Unspecified | 2020-02-20 | 2020-03-05 | 2020-03-19 | Arentz M, et al. |
Proportion of hospitalized cases that die | 0.523809524 | United States | Unspecified | Unspecified | Unspecified | 2020-02-20 | 2020-03-05 | 2020-03-19 | Arentz M, et al. |
Time from symptom onset to hospitalization | 3.5 | United States | Unspecified | Unspecified | Unspecified | 2020-02-20 | 2020-03-05 | 2020-03-19 | Arentz M, et al. |
Time from hospitalization to mechanical ventilation | 1.5 | United States | 0 | 12 | Unspecified | 2020-02-20 | 2020-03-05 | 2020-03-19 | Arentz M, et al. |
Proportion of hospitalized cases treated with antibiotics | 0.625 | China | Unspecified | Unspecified | 0-18 | 2020-01-24 | 2020-02-24 | 2020-03-19 | Sun , et al. |
Proportion of hospitalized cases treated with antivirals | 1 | China | Unspecified | Unspecified | 0-18 | 2020-01-24 | 2020-02-24 | 2020-03-19 | Sun , et al. |
Proportion of hospitalized cases on mechanical ventilation | 0.25 | China | Unspecified | Unspecified | 0-18 | 2020-01-24 | 2020-02-24 | 2020-03-19 | Sun , et al. |
Proportion of hospitalized cases that die | 0 | China | Unspecified | Unspecified | 0-18 | 2020-01-24 | 2020-02-24 | 2020-03-19 | Sun , et al. |
Effective reproduction number | 2.38 | China | 2.04 | 2.77 | Unspecified | 2020-01-10 | 2020-01-23 | 2020-03-16 | Li R, et al. |
Latent period | 3.69 | China | 3.28 | 4.03 | Unspecified | 2020-01-10 | 2020-01-23 | 2020-03-16 | Li R, et al. |
Transmission rate | 1.12 | China | 1.04 | 1.18 | Unspecified | 2020-01-10 | 2020-01-23 | 2020-03-16 | Li R, et al. |
Cumulative case count | 13118 | China | 2974 | 23435 | Unspecified | 2020-01-10 | 2020-01-23 | 2020-03-16 | Li R, et al. |
Cumulative case count | 16829 | China | 3797 | 30271 | Unspecified | 2020-01-10 | 2020-01-23 | 2020-03-16 | Li R, et al. |
Effective reproduction number | 1.36 | China | 1.14 | 1.63 | Unspecified | 2020-01-24 | 2020-02-03 | 2020-03-16 | Li R, et al. |
Latent period | 3.6 | China | 3.41 | 3.91 | Unspecified | 2020-01-24 | 2020-02-03 | 2020-03-16 | Li R, et al. |
Reporting rate | 75.00% | China | 60.00% | 69.00% | Unspecified | 2020-01-24 | 2020-02-03 | 2020-03-16 | Li R, et al. |
Transmission rate | 0.52 | China | 0.39 | 0.71 | Unspecified | 2020-01-24 | 2020-02-03 | 2020-03-16 | Li R, et al. |
Effective reproduction number | 0.99 | China | 0.76 | 1.33 | Unspecified | 2020-01-24 | 2020-02-08 | 2020-03-16 | Li R, et al. |
Latent period | 3.44 | China | 3.26 | 4.06 | Unspecified | 2020-01-24 | 2020-02-08 | 2020-03-16 | Li R, et al. |
Transmission rate | 0.35 | China | 0.27 | 0.5 | Unspecified | 2020-01-24 | 2020-02-08 | 2020-03-16 | Li R, et al. |
Proportion of infections acquired in hospital settings | 0.413043 | China | Unspecified | Unspecified | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Proportion of hospitalized cases treated with antibacterials | 1 | China | Unspecified | Unspecified | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Proportion of hospitalized cases treated with antivirals | 0.898551 | China | Unspecified | Unspecified | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Proportion of hospitalized cases admitted to icu | 0.26087 | China | Unspecified | Unspecified | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Proportion of icu patients that die | 0.166667 | China | Unspecified | Unspecified | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Proportion of hospitalized cases on mechanical ventilation | 0.123188 | China | Unspecified | Unspecified | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Proportion of hospitalized cases on extracorporeal membrane oxygenation (ecmo) | 0.028986 | China | Unspecified | Unspecified | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Proportion of hospitalized cases that die | 0.043478 | China | Unspecified | Unspecified | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Time from symptom onset to hospitalization | 7 | China | 4 | 8 | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Time from symptom onset to dyspena | 5 | China | 1 | 10 | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Time from symptom onset to ards | 8 | China | 6 | 12 | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Time from symptom onset to icu admission | 10 | China | 6 | 12 | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Duration of hospitalization | 10 | China | 7 | 14 | 42-68 | 2020-01-01 | 2020-02-03 | 2020-02-07 | Wang D, et al. |
Incubation period | 5.2 | China | 4.4 | 6 | Unspecified | 2019-12-01 | 2019-02-04 | 2020-02-04 | Lauer SA, et al. |
Ascertainment rate | 0.092 | Japan | 0.05 | 0.2 | Unspecified | 2020-01-22 | 2020-01-29 | 2020-02-04 | Nishiura H, et al. |
Cumulative case count | 75815 | China | 37304 | 130330 | Unspecified | 2019-12-01 | 2020-01-25 | 2020-01-31 | Wu JT, et al. |
Basic reproduction number | 2.24 | China | 1.96 | 2.55 | Unspecified | 2020-01-10 | 2020-01-24 | 2020-01-27 | Zhao S, et al. |
Proportion of hospitalized cases that die | 0.14 | China | 0.039 | 0.32 | Unspecified | Unspecified | 2020-01-21 | 2020-01-21 | Wu P, et al. |
Basic reproduction number | 0.3 | China | 0.17 | 0.44 | Unspecified | 2020-01-09 | 2020-01-11 | 2020-01-12 | Wu P, et al. |
Published estimates of epidemiological characteristics that have not been peer-reviewed, encoded by community members and approved by authors. For complete information on each estimate, view this file on GitHub.
name | value | country | lower bound | upper bound | age range | start date | end date | publication date | source |
---|---|---|---|---|---|---|---|---|---|
Infection fatality rate | 0.07% | Iran | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.13% | United States | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.02% | United States | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.40% | Switzerland | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.04% | Switzerland | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.02% | Japan | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.01% | Japan | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.34% | Denmark | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.05% | Denmark | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.03% | France | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.01% | France | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.31% | China | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.15% | China | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.68% | Netherlands | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.09% | Netherlands | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.25% | Germany | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.00% | Germany | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.11% | Brazil | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.04% | Brazil | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.06% | Scotland | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.01% | Scotland | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.17% | United States | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.06% | United States | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.58% | Luxembourg | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.06% | Luxembourg | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.21% | Germany | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.03% | Germany | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.18% | United States | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.05% | United States | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.54% | United States | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.23% | United States | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.12% | United States | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.03% | United States | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.27% | Brazil | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.09% | Brazil | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.14% | Croatia | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.02% | Croatia | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.33% | United States | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.14% | United States | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.48% | Switzerland | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.05% | Switzerland | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.77% | Italy | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.13% | Italy | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.03% | Japan | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Infection fatality rate | 0.01% | Japan | Unspecified | Unspecified | < 70 years | 2019-12-31 | 2020-06-07 | 2020-06-08 | Ioannidis JPA. |
Basic reproduction number | 4.06 | United States | 1.86 | 6.73 | Unspecified | 2020-01-21 | 2020-03-21 | 2020-05-22 | Liu Q, et al. |
Incubation period | 8.41 | United States | 6.64 | 9.42 | Unspecified | 2020-01-21 | 2020-03-21 | 2020-05-22 | Liu Q, et al. |
Incubation period | 10.69 | United States | 10.02 | 11.74 | Unspecified | 2020-03-22 | 2020-04-13 | 2020-05-22 | Liu Q, et al. |
Basic reproduction number | 1.15 | India | Unspecified | Unspecified | Unspecified | 2020-03-03 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.11 | India | Unspecified | Unspecified | Unspecified | 2020-03-11 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.58 | India | Unspecified | Unspecified | Unspecified | 2020-03-20 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 3.1 | India | Unspecified | Unspecified | Unspecified | 2020-03-18 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.19 | India | Unspecified | Unspecified | Unspecified | 2020-03-03 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.72 | India | Unspecified | Unspecified | Unspecified | 2020-03-03 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.68 | India | Unspecified | Unspecified | Unspecified | 2020-03-22 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.77 | India | Unspecified | Unspecified | Unspecified | 2020-03-04 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.96 | India | Unspecified | Unspecified | Unspecified | 2020-03-19 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.12 | India | Unspecified | Unspecified | Unspecified | 2020-03-19 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.28 | India | Unspecified | Unspecified | Unspecified | 2020-03-18 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 2.44 | India | Unspecified | Unspecified | Unspecified | 2020-03-14 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.41 | India | Unspecified | Unspecified | Unspecified | 2020-03-13 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.09 | India | Unspecified | Unspecified | Unspecified | 2020-03-12 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 7.92 | India | Unspecified | Unspecified | Unspecified | 2020-03-23 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 2.55 | India | Unspecified | Unspecified | Unspecified | 2020-03-05 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.74 | India | Unspecified | Unspecified | Unspecified | 2020-03-21 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.86 | India | Unspecified | Unspecified | Unspecified | 2020-04-02 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.87 | India | Unspecified | Unspecified | Unspecified | 2020-04-10 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.03 | India | Unspecified | Unspecified | Unspecified | 2020-03-20 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 3.44 | India | Unspecified | Unspecified | Unspecified | 2020-04-01 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 3.23 | India | Unspecified | Unspecified | Unspecified | 2020-03-22 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Basic reproduction number | 1.23 | India | Unspecified | Unspecified | Unspecified | 2020-03-24 | 2020-05-12 | 2020-05-19 | Jakhar M, et al. |
Infection fatality rate | 0.90% | Global | 0.70% | 1.16% | Unspecified | 2019-12-31 | 2020-05-31 | 2020-05-18 | Grewelle RE, et al. |
Incubation period | 6.4 | Vietnam | 4.89 | 8.5 | Unspecified | 2020-01-23 | 2020-04-13 | 2020-05-15 | Bui LV, et al. |
Basic reproduction number | 3.56 | France | Unspecified | Unspecified | Unspecified | 2020-02-15 | 2020-03-11 | 2020-05-01 | Unlu E, et al. |
Effective reproduction number | 0.74 | France | Unspecified | Unspecified | Unspecified | 2020-03-12 | 2020-05-01 | 2020-05-01 | Unlu E, et al. |
Incubation period | 5.1 | France | Unspecified | Unspecified | Unspecified | 2020-02-15 | 2020-05-01 | 2020-05-01 | Unlu E, et al. |
Proportion of infections symptomatic | 0.21 | France | Unspecified | Unspecified | Unspecified | 2020-02-15 | 2020-05-01 | 2020-05-01 | Unlu E, et al. |
Transmission rate | 0.34 | Algeria | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Algeria | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.14 | Algeria | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.09 | Algeria | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.22 | Argentina | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.05 | Argentina | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.08 | Argentina | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.04 | Argentina | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.44 | Australia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Australia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.18 | Australia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Australia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.57 | Austria | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Austria | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.23 | Austria | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Austria | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.69 | Belgium | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Belgium | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.28 | Belgium | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.08 | Belgium | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.7 | Brazil | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.03 | Brazil | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.28 | Brazil | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.06 | Brazil | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.68 | Canada | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.04 | Canada | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.27 | Canada | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.05 | Canada | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.49 | Chile | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.04 | Chile | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.2 | Chile | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.05 | Chile | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.26 | Colombia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Colombia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.1 | Colombia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Colombia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.45 | Czechia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Czechia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.19 | Czechia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Czechia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.22 | Denmark | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.22 | Denmark | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.08 | Denmark | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.08 | Denmark | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.26 | Dominican Republic | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.1 | Dominican Republic | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.1 | Dominican Republic | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.01 | Dominican Republic | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.32 | Ecuador | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Ecuador | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.13 | Ecuador | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Ecuador | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.22 | Egypt | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.14 | Egypt | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.08 | Egypt | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.03 | Egypt | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.18 | Finland | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.18 | Finland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.06 | Finland | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.06 | Finland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.64 | France | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | France | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.26 | France | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | France | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.73 | Germany | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Germany | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.29 | Germany | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Germany | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.18 | Greece | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Greece | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.05 | Greece | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.09 | Greece | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.41 | India | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.21 | India | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.17 | India | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.08 | India | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.27 | Indonesia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.24 | Indonesia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.1 | Indonesia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.09 | Indonesia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.39 | Iran | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Iran | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.16 | Iran | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Iran | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.35 | Ireland | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.35 | Ireland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.14 | Ireland | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.14 | Ireland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.61 | Israel | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.02 | Israel | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.25 | Israel | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.08 | Israel | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.55 | Italy | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Italy | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.23 | Italy | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Italy | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.16 | Japan | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.32 | Japan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.04 | Japan | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.13 | Japan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.2 | Luxembourg | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Luxembourg | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.07 | Luxembourg | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Luxembourg | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.34 | Malaysia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.02 | Malaysia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.14 | Malaysia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.07 | Malaysia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.31 | Mexico | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.15 | Mexico | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.12 | Mexico | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.03 | Mexico | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.52 | Netherlands | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Netherlands | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.21 | Netherlands | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Netherlands | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.32 | Norway | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.02 | Norway | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.13 | Norway | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.08 | Norway | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.2 | Pakistan | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.04 | Pakistan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.07 | Pakistan | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.05 | Pakistan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.22 | Panama | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Panama | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.08 | Panama | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Panama | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.31 | Peru | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.31 | Peru | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.13 | Peru | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.13 | Peru | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.31 | Philippines | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.11 | Philippines | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.12 | Philippines | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.01 | Philippines | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.28 | Poland | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Poland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.11 | Poland | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Poland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.5 | Portugal | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Portugal | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.21 | Portugal | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Portugal | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.06 | Qatar | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.38 | Qatar | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.03 | Qatar | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.16 | Qatar | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.59 | Romania | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.03 | Romania | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.24 | Romania | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.06 | Romania | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.47 | Russia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.32 | Russia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.2 | Russia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.13 | Russia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.24 | Saudi Arabia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.24 | Saudi Arabia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.09 | Saudi Arabia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.09 | Saudi Arabia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.29 | Serbia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.29 | Serbia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.12 | Serbia | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.12 | Serbia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.26 | Singapore | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.24 | Singapore | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.1 | Singapore | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.09 | Singapore | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.15 | South Africa | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.15 | South Africa | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.03 | South Africa | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.03 | South Africa | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.6 | Spain | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Spain | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.25 | Spain | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.08 | Spain | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.28 | Sweden | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Sweden | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.11 | Sweden | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Sweden | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.53 | Switzerland | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Switzerland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.22 | Switzerland | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Switzerland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.45 | Thailand | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.01 | Thailand | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.19 | Thailand | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.1 | Thailand | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.49 | Turkey | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.12 | Turkey | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.2 | Turkey | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.02 | Turkey | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.44 | United Arab Emirates | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.19 | United Arab Emirates | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.18 | United Arab Emirates | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.06 | United Arab Emirates | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.76 | United Kingdom | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.05 | United Kingdom | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.3 | United Kingdom | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.04 | United Kingdom | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.72 | United States | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Transmission rate | 0.02 | United States | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.29 | United States | Unspecified | Unspecified | Unspecified | 2019-12-31 | Unspecified | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | -0.07 | United States | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-26 | Romero-Severson E, et al. |
Growth rate | 0.2 | Belgium | 0.18 | 0.22 | Unspecified | 2020-03-06 | 2020-03-21 | 2020-04-15 | Ke R, et al. |
Growth rate | 0.22 | France | 0.2 | 0.25 | Unspecified | 2020-02-29 | 2020-03-14 | 2020-04-15 | Ke R, et al. |
Growth rate | 0.24 | Germany | 0.21 | 0.26 | Unspecified | 2020-03-01 | 2020-03-15 | 2020-04-15 | Ke R, et al. |
Growth rate | 0.24 | Italy | 0.22 | 0.26 | Unspecified | 2020-02-23 | 2020-03-08 | 2020-04-15 | Ke R, et al. |
Growth rate | 0.19 | Netherlands | 0.18 | 0.21 | Unspecified | 2020-03-06 | 2020-03-21 | 2020-04-15 | Ke R, et al. |
Growth rate | 0.29 | Spain | 0.27 | 0.31 | Unspecified | 2020-03-02 | 2020-03-16 | 2020-04-15 | Ke R, et al. |
Growth rate | 0.19 | Switzerland | 0.16 | 0.21 | Unspecified | 2020-03-05 | 2020-03-20 | 2020-04-15 | Ke R, et al. |
Growth rate | 0.2 | United Kingdom | 0.18 | 0.22 | Unspecified | 2020-03-05 | 2020-03-20 | 2020-04-15 | Ke R, et al. |
Growth rate | 0.28 | United States | 0.25 | 0.31 | Unspecified | 2020-03-03 | 2020-03-17 | 2020-04-15 | Ke R, et al. |
Basic reproduction number | Unspecified | global | 4 | 7.1 | Unspecified | 2020-01-20 | 2020-04-10 | 2020-04-15 | Ke R, et al. |
Growth rate | 0.34 | United States | 0.31 | 0.37 | Unspecified | 2020-03-04 | 2020-03-31 | 2020-04-14 | Bliznashki S. |
Growth rate | 0.23 | United States | 0.21 | 0.25 | Unspecified | 2020-03-04 | 2020-03-31 | 2020-04-14 | Bliznashki S. |
Growth rate | 0.2 | United States | 0.18 | 0.23 | Unspecified | 2020-03-04 | 2020-03-31 | 2020-04-14 | Bliznashki S. |
Date of emergence | 2020-02-01 | United States | 2020-01-18 | 2020-02-09 | Unspecified | 2020-02-20 | 2020-03-15 | 2020-04-06 | Bedford T, et al. |
Doubling time | 3.4 | United States | 2.4 | 5.1 | Unspecified | 2020-02-20 | 2020-03-15 | 2020-04-06 | Bedford T, et al. |
Cumulative case count | 400 | United States | 80 | 1300 | Unspecified | 2020-01-15 | 2020-03-01 | 2020-04-06 | Bedford T, et al. |
Cumulative case count | 9200000 | United States | 8000000 | 10100000 | Unspecified | 2020-03-15 | Unspecified | 2020-04-03 | Silverman JD, et al. |
Doubling time | 2.52 | United States | 2.519 | 2.521 | Unspecified | 2020-01-15 | Unspecified | 2020-04-03 | Silverman JD, et al. |
Doubling time | 2.455 | United States | 2.454 | 2.456 | Unspecified | 2020-01-15 | Unspecified | 2020-04-03 | Silverman JD, et al. |
Case fatality ratio | 0.023 | China | Unspecified | Unspecified | Unspecified | Unspecified | 2020-02-11 | 2020-04-02 | Dudel C, et al. |
Case fatality ratio | 0.04 | France | Unspecified | Unspecified | Unspecified | Unspecified | 2020-03-24 | 2020-04-02 | Dudel C, et al. |
Case fatality ratio | 0.086 | Spain | Unspecified | Unspecified | Unspecified | Unspecified | 2020-03-16 | 2020-04-02 | Dudel C, et al. |
Case fatality ratio | 0.016 | South Korea | Unspecified | Unspecified | Unspecified | Unspecified | 2020-03-30 | 2020-04-02 | Dudel C, et al. |
Case fatality ratio | 0.106 | Italy | Unspecified | Unspecified | Unspecified | Unspecified | 2020-03-29 | 2020-04-02 | Dudel C, et al. |
Case fatality ratio | 0.017 | United States | Unspecified | Unspecified | Unspecified | Unspecified | 2020-03-16 | 2020-04-02 | Dudel C, et al. |
Case fatality ratio | 0.012 | United States | Unspecified | Unspecified | Unspecified | Unspecified | 2020-03-24 | 2020-04-02 | Dudel C, et al. |
Case fatality ratio | 0.007 | Germany | Unspecified | Unspecified | Unspecified | Unspecified | 2020-03-29 | 2020-04-02 | Dudel C, et al. |
Cumulative case count | 749911 | NA | 561598 | 2814499 | Unspecified | Unspecified | Unspecified | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 184722 | NA | 178414 | 206180 | Unspecified | Unspecified | Unspecified | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 420685 | NA | 239546 | 5788917 | Unspecified | Unspecified | Unspecified | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 52686 | NA | 44867 | 104299 | Unspecified | Unspecified | Unspecified | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 7247 | NA | 5273 | 17720 | Unspecified | Unspecified | Unspecified | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 27272 | NA | 22879 | 49825 | Unspecified | Unspecified | Unspecified | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.37 | Afghanistan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-15 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 537 | Afghanistan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-15 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.51 | Albania | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 400 | Albania | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.36 | Algeria | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-04 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1389 | Algeria | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-04 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.72 | Andorra | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-02 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 690 | Andorra | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-02 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.42 | Argentina | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-04 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 2715 | Argentina | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-04 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.6 | Armenia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 599 | Armenia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.65 | Australia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 7247 | Australia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.59 | Austria | Unspecified | Unspecified | Unspecified | Unspecified | 2020-07-25 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 18671 | Austria | Unspecified | Unspecified | Unspecified | Unspecified | 2020-07-25 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.23 | Azerbaijan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-28 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 428 | Azerbaijan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-28 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.01 | Bahrain | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-09 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 524 | Bahrain | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-09 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.55 | Belgium | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 15097 | Belgium | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.14 | Bosnia and Herzegovina | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-28 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 678 | Bosnia and Herzegovina | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-28 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.7 | Brazil | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-08 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 25424 | Brazil | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-08 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.48 | Brunei Darussalam | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 249 | Brunei Darussalam | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.25 | Bulgaria | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-24 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1199 | Bulgaria | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-24 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.3 | Burkina Faso | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-06 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1218 | Burkina Faso | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-06 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.67 | Canada | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 13468 | Canada | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.62 | Chile | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 5258 | Chile | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.28 | China | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-03 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 85166 | China | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-03 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.41 | Colombia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-21 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 3744 | Colombia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-21 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.27 | Costa Rica | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 821 | Costa Rica | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.55 | Côte d’Ivoire | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-10 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1319 | Côte d’Ivoire | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-10 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.67 | Croatia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-20 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1273 | Croatia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-20 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.29 | Cyprus | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 438 | Cyprus | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.45 | Czech Republic | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 5218 | Czech Republic | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.41 | Denmark | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-15 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 3555 | Denmark | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-15 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.54 | Dominican Republic | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-20 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 2017 | Dominican Republic | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-20 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.53 | Ecuador | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-26 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 5191 | Ecuador | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-26 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.3 | Egypt | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-24 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 844 | Egypt | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-24 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.68 | Estonia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-06-24 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 838 | Estonia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-06-24 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.07 | Faroe Islands | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-09 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 226 | Faroe Islands | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-09 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.2 | Finland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-26 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1702 | Finland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-26 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 3.61 | France | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-19 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 63851 | France | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-19 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.72 | Germany | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-21 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 105903 | Germany | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-21 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.53 | Ghana | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-05 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 4488 | Ghana | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-05 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.27 | Greece | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-19 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1496 | Greece | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-19 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.27 | Hungary | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-27 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1084 | Hungary | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-27 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.15 | Iceland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1524 | Iceland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.41 | India | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-09 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 3326 | India | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-09 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.43 | Indonesia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-13 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 4638 | Indonesia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-13 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 3.55 | Iran | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-11 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 45932 | Iran | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-11 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.86 | Iraq | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-22 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 668 | Iraq | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-22 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.59 | Ireland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-29 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 5707 | Ireland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-29 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.78 | Israel | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-25 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 10740 | Israel | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-25 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.67 | Italy | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 127283 | Italy | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 3.22 | Japan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-24 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1737 | Japan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-24 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.28 | Jordan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-10 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 949 | Jordan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-10 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.33 | Kazakhstan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-04 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 2329 | Kazakhstan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-04 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.31 | Korea | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-08 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 10451 | Korea | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-08 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 1.68 | Kuwait | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-20 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 295 | Kuwait | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-20 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.23 | Latvia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-28 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 600 | Latvia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-28 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.2 | Lebanon | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-25 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 786 | Lebanon | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-25 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.73 | Lithuania | Unspecified | Unspecified | Unspecified | Unspecified | 2020-06-10 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1069 | Lithuania | Unspecified | Unspecified | Unspecified | Unspecified | 2020-06-10 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.44 | Luxembourg | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-20 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 4316 | Luxembourg | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-20 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.39 | Malaysia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 4296 | Malaysia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.22 | Malta | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-26 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 310 | Malta | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-26 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.36 | Mexico | Unspecified | Unspecified | Unspecified | Unspecified | 2020-06-17 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 4308 | Mexico | Unspecified | Unspecified | Unspecified | Unspecified | 2020-06-17 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.28 | Moldova | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 775 | Moldova | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.41 | Morocco | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-15 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 2397 | Morocco | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-15 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.61 | Netherlands | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-25 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 20893 | Netherlands | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-25 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.62 | New Zealand | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-20 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 2102 | New Zealand | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-20 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.67 | North Macedonia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-17 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 486 | North Macedonia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-17 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.34 | Norway | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 7002 | Norway | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.21 | Oman | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 230 | Oman | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.35 | Pakistan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-13 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 4939 | Pakistan | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-13 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.64 | Panama | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-24 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 2854 | Panama | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-24 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.29 | Peru | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-01 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 3992 | Peru | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-01 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.35 | Philippines | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-09 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 2972 | Philippines | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-09 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.51 | Poland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-24 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 5586 | Poland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-24 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.66 | Portugal | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-05 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 13108 | Portugal | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-05 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.46 | Qatar | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 819 | Qatar | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.65 | Réunion | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-27 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 429 | Réunion | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-27 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.52 | Romania | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 3413 | Romania | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-18 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.52 | Russia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-14 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 6774 | Russia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-14 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.14 | San Marino | Unspecified | Unspecified | Unspecified | Unspecified | 2020-06-04 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 311 | San Marino | Unspecified | Unspecified | Unspecified | Unspecified | 2020-06-04 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.47 | Saudi Arabia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-27 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 4335 | Saudi Arabia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-27 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.34 | Senegal | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-29 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 280 | Senegal | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-29 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.25 | Serbia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-21 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1481 | Serbia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-21 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 3.15 | Singapore | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 847 | Singapore | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-16 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.27 | Slovakia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-25 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 879 | Slovakia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-25 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.76 | Slovenia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-25 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1168 | Slovenia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-25 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.7 | South Africa | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-10 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 13614 | South Africa | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-10 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.66 | Spain | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-22 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 152539 | Spain | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-22 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.28 | Sri Lanka | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 200 | Sri Lanka | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.21 | Sweden | Unspecified | Unspecified | Unspecified | Unspecified | 2020-07-23 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 3974 | Sweden | Unspecified | Unspecified | Unspecified | Unspecified | 2020-07-23 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.64 | Switzerland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-24 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 28290 | Switzerland | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-24 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.32 | Thailand | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-15 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 5112 | Thailand | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-15 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.69 | The United Kingdom | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-02 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 41228 | The United Kingdom | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-02 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.38 | Tunisia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-28 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 1723 | Tunisia | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-28 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 3.11 | Turkey | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-06 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 76824 | Turkey | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-06 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.69 | Ukraine | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-03 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 10285 | Ukraine | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-03 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.21 | United Arab Emirates | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 643 | United Arab Emirates | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-23 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.82 | United States | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-07 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 400892 | United States | Unspecified | Unspecified | Unspecified | Unspecified | 2020-05-07 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.64 | Uruguay | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-26 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 2030 | Uruguay | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-26 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.42 | Venezuela | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-21 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 657 | Venezuela | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-21 | 2020-04-01 | Liu Q, et al. |
Basic reproduction number | 2.31 | Viet Nam | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Cumulative case count | 211 | Viet Nam | Unspecified | Unspecified | Unspecified | Unspecified | 2020-04-17 | 2020-04-01 | Liu Q, et al. |
Transmission rate | 0.315 | Brazil | Unspecified | Unspecified | Unspecified | 2020-02-26 | 2020-03-25 | 2020-03-30 | Crokidakis N. |
Basic reproduction number | 5.25 | Brazil | Unspecified | Unspecified | Unspecified | 2020-02-26 | 2020-03-25 | 2020-03-30 | Crokidakis N. |
Doubling time | 2.72 | Brazil | Unspecified | Unspecified | Unspecified | 2020-02-26 | 2020-03-25 | 2020-03-30 | Crokidakis N. |
Serial interval | 4.95 | China | -0.29 | 10.19 | Unspecified | 2020-01-20 | 2020-02-19 | 2020-03-30 | Xu X, et al. |
Serial interval | 5.19 | China | -0.09 | 10.47 | Unspecified | 2020-01-20 | 2020-02-19 | 2020-03-30 | Xu X, et al. |
Case fatality ratio | 0.0048 | South Korea | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-03-13 | 2020-03-29 | Lv B, et al. |
Case fatality ratio | 0.017 | Japan | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-03-13 | 2020-03-29 | Lv B, et al. |
Case fatality ratio | 0.043 | Iran | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-03-13 | 2020-03-29 | Lv B, et al. |
Case fatality ratio | 0.066 | Italy | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-03-13 | 2020-03-29 | Lv B, et al. |
Case fatality ratio | 0.029 | United States | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-03-13 | 2020-03-29 | Lv B, et al. |
Case fatality ratio | 0.021 | France | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-03-13 | 2020-03-29 | Lv B, et al. |
Case fatality ratio | 0.028 | Spain | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-03-13 | 2020-03-29 | Lv B, et al. |
Basic reproduction number | 2.55 | Algeria | 2.15 | 2.93 | Unspecified | 2020-02-25 | 2020-03-22 | 2020-03-27 | Hamidouche M. |
Case fatality rate | 2.6% | NA | 0.89% | 6.7% | Unspecified | 2020-01-19 | 2020-02-20 | 2020-03-26 | Russell TW, et al. |
Infection fatality ratio | 1.3% | NA | 0.38% | 3.6% | Unspecified | 2020-01-19 | 2020-02-20 | 2020-03-26 | Russell TW, et al. |
Case fatality rate | 13% | NA | 5.2% | 26% | 70-130 | 2020-01-19 | 2020-02-20 | 2020-03-26 | Russell TW, et al. |
Infection fatality ratio | 6.4% | NA | 2.6% | 13% | 70-130 | 2020-01-19 | 2020-02-20 | 2020-03-26 | Russell TW, et al. |
Case fatality rate | 1.20% | NA | 0.30% | 3.1% | Unspecified | Unspecified | 2020-03-03 | 2020-03-26 | Russell TW, et al. |
Infection fatality ratio | 0.6% | NA | 0.20% | 1.7% | Unspecified | Unspecified | 2020-03-03 | 2020-03-26 | Russell TW, et al. |
Basic reproduction number | 3.15 | China | 1.71 | 5.21 | Unspecified | 2020-01-23 | Unspecified | 2020-03-20 | Wangping J, et al. |
Cumulative case count | 3988 | China | 786 | 9065 | Unspecified | 2020-01-23 | Unspecified | 2020-03-20 | Wangping J, et al. |
Basic reproduction number | 4.1 | Italy | 2.15 | 6.77 | Unspecified | 2020-03-09 | Unspecified | 2020-03-20 | Wangping J, et al. |
Cumulative case count | 30086 | Italy | 7920 | 81869 | Unspecified | 2020-03-09 | Unspecified | 2020-03-20 | Wangping J, et al. |
Basic reproduction number | 3.26 | Italy | 1.83 | 5.34 | Unspecified | 2020-03-05 | Unspecified | 2020-03-20 | Wangping J, et al. |
Cumulative case count | 10636 | Italy | 2357 | 23326 | Unspecified | 2020-03-05 | Unspecified | 2020-03-20 | Wangping J, et al. |
Basic reproduction number | 4.24 | Italy | 2.44 | 6.61 | Unspecified | 2020-03-15 | Unspecified | 2020-03-20 | Wangping J, et al. |
Cumulative case count | 44993 | Italy | 16676 | 96759 | Unspecified | 2020-03-15 | Unspecified | 2020-03-20 | Wangping J, et al. |
Time from symptom onset to reporting | 7.3 | Italy | 1 | 20 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-20 | Cereda D, et al. |
Serial interval | 6.6 | Italy | 0.7 | 19 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-20 | Cereda D, et al. |
Doubling time | 2.6 | Italy | 2.2 | 3 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-20 | Cereda D, et al. |
Doubling time | 3.1 | Italy | 2.2 | 5.4 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-20 | Cereda D, et al. |
Doubling time | 3.5 | Italy | 2.7 | 4.8 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-20 | Cereda D, et al. |
Doubling time | 3.4 | Italy | 2.5 | 5 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-20 | Cereda D, et al. |
Basic reproduction number | 3.1 | Italy | 2.9 | 3.2 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-20 | Cereda D, et al. |
Basic reproduction number | 2.5 | Italy | 2.1 | 2.8 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-20 | Cereda D, et al. |
Basic reproduction number | 2.3 | Italy | 1.9 | 2.7 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-20 | Cereda D, et al. |
Basic reproduction number | 3.1 | Italy | 2.9 | 3.2 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-20 | Cereda D, et al. |
Basic reproduction number | 2.5 | Japan | 2.43 | 2.55 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-16 | Sugishita Y, et al. |
Effective reproduction number | 1.88 | Japan | 1.68 | 2.02 | Unspecified | 2020-01-14 | 2020-03-08 | 2020-03-16 | Sugishita Y, et al. |
Cumulative case count | 1294 | Italy | 390 | 3034 | Unspecified | Unspecified | 2020-03-04 | 2020-03-13 | Jombart T, et al. |
Cumulative case count | 202 | Spain | 95 | 823 | Unspecified | Unspecified | 2020-03-04 | 2020-03-13 | Jombart T, et al. |
Cumulative case count | 592 | France | 177 | 1705 | Unspecified | Unspecified | 2020-03-04 | 2020-03-13 | Jombart T, et al. |
Basic reproduction number | 3.8 | China | 3.5 | 4.2 | Unspecified | 2020-01-10 | 2020-01-23 | 2020-03-13 | Tang B, et al. |
Basic reproduction number | 3 | China | 2.6 | 3.3 | Unspecified | 2020-01-19 | 2020-01-31 | 2020-03-13 | Tang B, et al. |
Basic reproduction number | 2.6 | South Korea | 2.5 | 2.7 | Unspecified | 2020-01-23 | 2020-03-02 | 2020-03-13 | Tang B, et al. |
Effective reproduction number | 0.9 | Singapore | 0.7 | 1 | Unspecified | 2020-01-21 | 2020-03-05 | 2020-03-12 | Amna Tari, et al. |
Epidemic size | 294.4 | Singapore | 101.1 | 1239.7 | Unspecified | 2020-01-21 | 2020-03-05 | 2020-03-12 | Amna Tari, et al. |
Growth rate | 1.1 | Singapore | 0.4 | 2 | Unspecified | 2020-01-21 | 2020-03-05 | 2020-03-12 | Amna Tari, et al. |
Dispersion | 0.4 | Singapore | 0.1 | Inf | Unspecified | 2020-01-21 | 2020-03-05 | 2020-03-12 | Amna Tari, et al. |
Basic reproduction number | 3.6 | Iran | 3.2 | 4.2 | Unspecified | 2020-02-19 | 2020-02-29 | 2020-03-10 | Muniz-Rodriguez K, et al. |
Growth rate | 0.85 | Iran | 0.69 | 1 | Unspecified | 2020-02-19 | 2020-02-29 | 2020-03-10 | Muniz-Rodriguez K, et al. |
Basic reproduction number | 3.58 | Iran | 1.29 | 8.46 | Unspecified | 2020-02-19 | 2020-02-29 | 2020-03-10 | Muniz-Rodriguez K, et al. |
Doubling time | 1.2 | Iran | 1.05 | 1.44 | Unspecified | 2020-02-19 | 2020-02-29 | 2020-03-10 | Muniz-Rodriguez K, et al. |
Ascertainment rate | 0.44 | Japan | 0.37 | 0.5 | Unspecified | Unspecified | 2020-02-28 | 2020-03-10 | Omori R, et al. |
Incubation period | 8.13 | China | 7.37 | 8.91 | Unspecified | 2020-01-12 | 2020-01-23 | 2020-03-10 | Qin J, et al. |
Incubation period | 8.62 | China | 8.02 | 9.28 | Unspecified | 2020-01-12 | 2020-01-23 | 2020-03-10 | Qin J, et al. |
Generation interval | 5.2 | Singapore | 3.78 | 6.78 | Unspecified | 2019-12-31 | 2020-02-26 | 2020-03-08 | Ganyani T, et al. |
Serial interval | 5.21 | Singapore | -3.35 | 13.94 | Unspecified | 2019-12-31 | 2020-02-26 | 2020-03-08 | Ganyani T, et al. |
Basic reproductive number | 1.27 | Singapore | 1.19 | 1.36 | Unspecified | 2019-12-31 | 2020-02-26 | 2020-03-08 | Ganyani T, et al. |
Generation interval | 3.95 | China | 3.01 | 4.91 | Unspecified | 2019-12-31 | 2020-02-27 | 2020-03-08 | Ganyani T, et al. |
Serial interval | 3.95 | China | -4.47 | 12.51 | Unspecified | 2019-12-31 | 2020-02-27 | 2020-03-08 | Ganyani T, et al. |
Basic reproductive number | 1.59 | China | 1.42 | 1.78 | Unspecified | 2019-12-31 | 2020-02-27 | 2020-03-08 | Ganyani T, et al. |
Incubation period | 6.6 | Singapore | 1.8 | 11.4 | Unspecified | 2020-01-19 | 2020-02-26 | 2020-03-06 | Tindale LC, et al. |
Time from symptom onset to hospitalization | 5.9 | Singapore | 0.8 | 11 | Unspecified | 2020-01-19 | 2020-02-26 | 2020-03-06 | Tindale LC, et al. |
Time from hospitalization to recovery | 13.3 | Singapore | 7.3 | 19.3 | Unspecified | 2020-01-19 | 2020-02-26 | 2020-03-06 | Tindale LC, et al. |
Incubation period | 5.4 | China | 0.9 | 9.9 | Unspecified | 2020-01-21 | 2020-02-22 | 2020-03-06 | Tindale LC, et al. |
Incubation period | 5.2 | China | 1 | 9.4 | Unspecified | 2020-01-21 | 2020-02-22 | 2020-03-06 | Tindale LC, et al. |
Case fatality rate | 2.2 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-02-22 | 2020-03-06 | Tindale LC, et al. |
Incubation period | 7.1 | Singapore | 6.1 | 8.3 | Unspecified | 2020-01-19 | 2020-02-26 | 2020-03-06 | Tindale LC, et al. |
Incubation period | 5.46 | Singapore | 1.34 | 11.1 | Unspecified | 2020-01-19 | 2020-01-31 | 2020-03-06 | Tindale LC, et al. |
Incubation period | 7.27 | Singapore | 1.31 | 17.3 | Unspecified | 2020-02-01 | 2020-02-26 | 2020-03-06 | Tindale LC, et al. |
Incubation period | 9 | China | 7.92 | 10.2 | Unspecified | 2020-01-21 | 2020-02-22 | 2020-03-06 | Tindale LC, et al. |
Incubation period | 6.9 | China | 2 | 12.7 | Unspecified | 2020-01-21 | 2020-01-31 | 2020-03-06 | Tindale LC, et al. |
Incubation period | 12.4 | China | 5.4 | 19 | Unspecified | 2020-02-01 | 2020-02-22 | 2020-03-06 | Tindale LC, et al. |
Serial interval | 4.56 | Singapore | 2.69 | 6.42 | Unspecified | 2020-01-19 | 2020-02-26 | 2020-03-06 | Tindale LC, et al. |
Serial interval | 4.22 | China | 3.43 | 5.01 | Unspecified | 2020-01-21 | 2020-02-22 | 2020-03-06 | Tindale LC, et al. |
Incubation period | 4.8 | China | 4.2 | 5.4 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 20.3 | China | 19.4 | 21.3 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 21.2 | China | 20.2 | 22.3 | 0-9 | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 17.5 | China | 15.3 | 20 | 10-19 | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 19.1 | China | 15.8 | 22.9 | 20-29 | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 19.2 | China | 17.5 | 21 | 30-39 | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 19.2 | China | 18 | 20.5 | 40-49 | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 21.6 | China | 20 | 23.4 | 50-59 | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 22.4 | China | 20.8 | 24.1 | 60-69 | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 22.9 | China | 21.2 | 24.7 | 70-130 | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 22.5 | China | 19.1 | 26.3 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 20.1 | China | 19 | 21.3 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 20.3 | China | 19.5 | 21.1 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 28.3 | China | 25.3 | 31.6 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 19.3 | China | 17.9 | 20.9 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 21.2 | China | 20.4 | 22 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to recovery | 21.2 | China | 18 | 24.9 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Secondary attack rate | 14.9 | China | 12.1 | 18.2 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Secondary attack rate | 9.6 | China | 7.9 | 11.8 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Serial interval | 6.3 | China | 5.2 | 7.6 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Effective reproduction number | 0.4 | China | 0.3 | 0.5 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to isolation | 2.7 | China | 2.1 | 3.3 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to isolation | 4.6 | China | 4.1 | 5 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to pcr confirmation | 3.18 | China | 2.65 | 3.76 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Time from symptom onset to pcr confirmation | 5.46 | China | 4.99 | 5.92 | Unspecified | 2020-01-14 | 2020-02-12 | 2020-03-04 | Qifang B, et al. |
Basic reproduction number | 4.8 | China | 3.36 | 6.67 | Unspecified | 2020-01-11 | 2020-01-16 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 4.6 | China | 3.56 | 5.65 | Unspecified | 2020-01-11 | 2020-01-17 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 5.14 | China | 4.25 | 6.03 | Unspecified | 2020-01-11 | 2020-01-18 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 6.09 | China | 5.02 | 7.16 | Unspecified | 2020-01-11 | 2020-01-19 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 7.09 | China | 5.84 | 8.35 | Unspecified | 2020-01-11 | 2020-01-20 | 2020-03-03 | Anastassopoulou C, et al. |
Symptomatic case fatality ratio | 2.94 | China | 2.9 | 3 | Unspecified | 2020-01-11 | 2020-02-10 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 2.6 | China | Unspecified | Unspecified | Unspecified | 2020-01-11 | 2020-02-10 | 2020-03-03 | Anastassopoulou C, et al. |
Cumulative case count | 180000 | China | 45000 | 760000 | Unspecified | 2020-01-11 | 2020-02-29 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 3.25 | China | 2.37 | 4.14 | Unspecified | 2020-01-11 | 2020-01-16 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 3.13 | China | 2.5 | 3.76 | Unspecified | 2020-01-11 | 2020-01-17 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 3.42 | China | 2.91 | 3.93 | Unspecified | 2020-01-11 | 2020-01-18 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 3.96 | China | 3.36 | 4.57 | Unspecified | 2020-01-11 | 2020-01-19 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 4.58 | China | 3.81 | 5.35 | Unspecified | 2020-01-11 | 2020-01-20 | 2020-03-03 | Anastassopoulou C, et al. |
Basic reproduction number | 2 | China | Unspecified | Unspecified | Unspecified | 2020-01-11 | 2020-02-10 | 2020-03-03 | Anastassopoulou C, et al. |
Cumulative case count | 8000000 | China | 720000 | 37000000 | Unspecified | 2020-01-11 | 2020-02-29 | 2020-03-03 | Anastassopoulou C, et al. |
Case fatality rate | 0.8-0.9 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-03-01 | 2020-03-03 | Rui Q, et al. |
Case fatality rate | 5.4 | China | Unspecified | Unspecified | Unspecified | 2020-01-21 | 2020-03-01 | 2020-03-03 | Rui Q, et al. |
Case fatality rate | 0.8-0.9 | China | NA | NA | Unspecified | 2020-01-21 | 2020-03-01 | 2020-03-03 | Qi R, et al. |
Case fatality rate | 5.4 | China | NA | NA | Unspecified | 2020-01-21 | 2020-03-01 | 2020-03-03 | Qi R, et al. |
Basic reproduction number | 2.2 | Cruise Ship | 2.1 | 2.4 | Unspecified | 2020-01-20 | 2020-02-20 | 2020-03-02 | Zhao S, et al. |
Dispersion | 44 | Cruise Ship | 6 | 88 | Unspecified | 2020-01-20 | 2020-02-20 | 2020-03-02 | Zhao S, et al. |
Cumulative case count | 3066 | Cruise Ship | 2046 | 3441 | Unspecified | 2020-01-20 | 2020-02-20 | 2020-03-02 | Zhao S, et al. |
Doubling time | 4.6 | Cruise Ship | 3 | 9.3 | Unspecified | 2020-01-20 | 2020-02-20 | 2020-03-02 | Zhao S, et al. |
Effective reproduction number | 1.5 | South Korea | 1.4 | 1.6 | Unspecified | 2020-01-20 | 2020-02-26 | 2020-03-02 | Shim E, et al. |
Growth rate | 0.6 | South Korea | 0.5 | 0.7 | Unspecified | 2020-01-20 | 2020-02-26 | 2020-03-02 | Shim E, et al. |
Cumulative case count | 79467 | China | 71576 | 93855 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 64261 | China | 58223 | 77895 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 46607 | China | 40812 | 57678 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 13906 | China | 12748 | 16092 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 1410 | China | 1324 | 1550 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 1265 | China | 1204 | 1364 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 1369 | China | 1271 | 1559 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 1136 | China | 1050 | 1279 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 1100 | China | 1021 | 1273 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 1123 | China | 948 | 1146 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 429 | China | 395 | 486 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 356 | China | 334 | 388 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 365 | China | 346 | 393 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Cumulative case count | 430 | China | 407 | 461 | Unspecified | 2020-01-21 | 2020-02-14 | 2020-02-20 | Fu X, et al. |
Proportion of hospitalized cases admitted to icu | 0.05 | China | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-02-18 | 2020-02-18 | Zhou G, et al. |
Cumulative case count | 2868.7 | China | 1129.7 | 4607.7 | Unspecified | 2019-12-31 | 2020-01-23 | 2020-02-18 | Zhou G, et al. |
Cumulative case count | 52185.4 | China | 20564 | 83806.8 | Unspecified | 2020-01-23 | 2020-02-12 | 2020-02-18 | Zhou G, et al. |
Cumulative case count | 45000 | China | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-02-12 | 2020-02-18 | Wan K, et al. |
Basic reproduction number | 1.44 | China | 1.4 | 1.47 | Unspecified | 2020-01-22 | 2020-02-12 | 2020-02-18 | Wan K, et al. |
Cumulative case count | 453 | China | Unspecified | Unspecified | Unspecified | 2019-12-08 | 2020-01-22 | 2020-02-18 | Zhang B, et al. |
Cumulative case count | 6333 | China | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-02-13 | 2020-02-18 | Zhang B, et al. |
Cumulative case count | 24333 | China | Unspecified | Unspecified | Unspecified | 2020-02-14 | Unspecified | 2020-02-18 | Zhang B, et al. |
Effective reproduction number | 3.6 | China | Unspecified | Unspecified | Unspecified | 2019-12-08 | 2020-01-22 | 2020-02-18 | Zhang B, et al. |
Effective reproduction number | 1.55 | China | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-02-13 | 2020-02-18 | Zhang B, et al. |
Effective reproduction number | 1.08 | China | Unspecified | Unspecified | Unspecified | 2020-02-14 | Unspecified | 2020-02-18 | Zhang B, et al. |
Cumulative case count | 7710 | China | Unspecified | Unspecified | Unspecified | 2020-01-10 | 2020-01-22 | 2020-02-18 | Zhang B, et al. |
Cumulative case count | 18832 | China | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-02-13 | 2020-02-18 | Zhang B, et al. |
Cumulative case count | 21342 | China | 21057 | 21629 | Unspecified | 2020-02-14 | Unspecified | 2020-02-18 | Zhang B, et al. |
Effective reproduction number | 3.4 | China | Unspecified | Unspecified | Unspecified | 2020-01-10 | 2020-01-22 | 2020-02-18 | Zhang B, et al. |
Effective reproduction number | 0.83 | China | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-02-13 | 2020-02-18 | Zhang B, et al. |
Effective reproduction number | 0.59 | China | Unspecified | Unspecified | Unspecified | 2020-02-14 | Unspecified | 2020-02-18 | Zhang B, et al. |
Cumulative case count | 7793 | China | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-02-03 | 2020-02-18 | Zhang B, et al. |
Cumulative case count | 13384 | China | Unspecified | Unspecified | Unspecified | 2020-02-04 | Unspecified | 2020-02-18 | Zhang B, et al. |
Effective reproduction number | 3.3 | China | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-02-03 | 2020-02-18 | Zhang B, et al. |
Effective reproduction number | 0.63 | China | Unspecified | Unspecified | Unspecified | 2020-02-04 | Unspecified | 2020-02-18 | Zhang B, et al. |
Time from symptom onset to reporting | 5.1 | China | 3.5 | 7.5 | Unspecified | 2019-12-31 | 2020-01-24 | 2020-02-17 | Jung S, et al. |
Time from symptom onset to death | 15.2 | China | 13.1 | 17.7 | Unspecified | 2019-12-31 | 2020-01-24 | 2020-02-17 | Jung S, et al. |
Cumulative case count | 6924 | China | 4885 | 9211 | Unspecified | 2019-12-08 | 2020-01-24 | 2020-02-17 | Jung S, et al. |
Proportion of symptomatics that die | 5.30% | China | 3.50% | 7.50% | Unspecified | 2019-12-08 | 2020-01-24 | 2020-02-17 | Jung S, et al. |
Basic reproduction number | 2.1 | China | 2 | 2.2 | Unspecified | 2019-12-08 | 2020-01-24 | 2020-02-17 | Jung S, et al. |
Cumulative case count | 19289 | China | 10901 | 30158 | Unspecified | 2019-12-08 | 2020-01-24 | 2020-02-17 | Jung S, et al. |
Proportion of symptomatics that die | 8.40% | China | 5.30% | 12.30% | Unspecified | 2019-12-08 | 2020-01-24 | 2020-02-17 | Jung S, et al. |
Basic reproduction number | 3.2 | China | 2.7 | 3.7 | Unspecified | 2019-12-08 | 2020-01-24 | 2020-02-17 | Jung S, et al. |
Cumulative case count | 4090 | China | 3975 | 4206 | Unspecified | 2019-11-30 | 2020-01-11 | 2020-02-13 | Lin Q, et al. |
Cumulative case count | 56833 | China | 55242 | 58449 | Unspecified | 2019-11-30 | 2020-02-09 | 2020-02-13 | Lin Q, et al. |
Cumulative case count | 110000 | China | 40000 | 310000 | Unspecified | 2020-01-29 | 2020-02-02 | 2020-02-13 | Zhao H, et al. |
Basic reproduction number | 7.05 | China | 6.11 | 8.18 | Unspecified | 2019-12-31 | 2020-01-23 | 2020-02-13 | Mizumoto K, et al. |
Effective reproduction number | 3.24 | China | 3.16 | 3.32 | Unspecified | 2020-01-23 | 2020-02-13 | 2020-02-13 | Mizumoto K, et al. |
Cumulative case count | 983006 | China | 759575 | 1296258 | Unspecified | 2019-12-31 | 2020-02-13 | 2020-02-13 | Mizumoto K, et al. |
Proportion of symptomatics that die | 0.0406 | China | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-02-13 | 2020-02-13 | Mizumoto K, et al. |
Cumulative case count | 3491 | China | 1924 | 7360 | Unspecified | 2019-12-01 | 2020-01-22 | 2020-02-11 | Chinazzi M, et al. |
Cumulative case count | 58956 | China | 40760 | 87471 | Unspecified | 2019-12-01 | 2020-01-22 | 2020-02-11 | Chinazzi M, et al. |
Ascertainment rate | 0.1959 | China | 0.1436 | 0.3558 | Unspecified | 2019-12-01 | 2020-02-05 | 2020-02-11 | Chinazzi M, et al. |
Incubation period | 4.2 | China | 3.5 | 5.1 | Unspecified | 2019-12-31 | 2020-02-10 | 2020-02-11 | Sanche S, et al. |
Time from hospitalization to recovery | 11.5 | China | 8 | 17.3 | Unspecified | 2019-12-31 | 2020-02-10 | 2020-02-11 | Sanche S, et al. |
Time from hospitalization to death | 11.2 | China | 8.7 | 14.9 | Unspecified | 2019-12-31 | 2020-02-10 | 2020-02-11 | Sanche S, et al. |
Growth rate | 0.29 | China | 0.21 | 0.37 | Unspecified | 2019-12-31 | 2020-01-29 | 2020-02-11 | Sanche S, et al. |
Cumulative case count | 4100 | China | 2423 | 6178 | Unspecified | 2019-12-31 | 2020-01-18 | 2020-02-11 | Sanche S, et al. |
Cumulative case count | 18700 | China | 7141 | 38663 | Unspecified | 2020-01-19 | 2020-01-23 | 2020-02-11 | Sanche S, et al. |
Growth rate | 0.14 | China | 0.12 | 0.15 | Unspecified | 2020-01-30 | 2020-02-10 | 2020-02-11 | Sanche S, et al. |
Proportion of symptomatics that die | 0.18 | China | 0.11 | 0.81 | Unspecified | 2019-12-31 | 2020-02-05 | 2020-02-10 | Dorigatt I, et al. |
Time from symptom onset to death | 22.3 | China | 18 | 82 | Unspecified | 2019-12-31 | 2020-01-21 | 2020-02-10 | Dorigatt I, et al. |
Cumulative case count | 24000 | China | 13000 | 44000 | Unspecified | 2019-12-31 | 2020-01-31 | 2020-02-10 | Dorigatt I, et al. |
Ascertainment rate | 0.0012 | China | 0.0009 | 0.0015 | Unspecified | 2020-01-01 | 2020-01-22 | 2020-02-09 | Cao Z, et al. |
Cumulative case count | 35454 | China | Unspecified | Unspecified | Unspecified | Unspecified | 2020-01-23 | 2020-02-09 | Cao Z, et al. |
Basic reproduction number | 1.48 | China | Unspecified | Unspecified | Unspecified | 2019-12-17 | 2020-02-06 | 2020-02-08 | Hermanowic, et al. |
Effective reproduction number | 1.06 | China | Unspecified | Unspecified | Unspecified | 2019-12-17 | 2020-02-08 | 2020-02-08 | Hermanowic, et al. |
Basic reproduction number | 2.4 – 2.5 | China | Unspecified | Unspecified | Unspecified | 2019-12-17 | 2020-02-06 | 2020-02-08 | Hermanowic, et al. |
Cumulative case count | 65000 | China | Unspecified | Unspecified | Unspecified | 2019-12-17 | 2020-02-06 | 2020-02-08 | Hermanowic, et al. |
Doubling time | 2.4 | China | Unspecified | Unspecified | Unspecified | 2020-01-20 | 2020-02-02 | 2020-02-06 | Muniz-Rodriguez K, et al. |
Proportion of hospitalized cases that die | 33 | China | 29 | 37 | Unspecified | 2019-12-10 | 2020-01-27 | 2020-02-04 | Famular, et al. |
Ascertainment rate | 1 | China | 0.6 | 2 | Unspecified | 2019-12-10 | 2020-01-27 | 2020-02-04 | Famular, et al. |
Cumulative case count | 58000 | China | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-01-31 | 2020-01-31 | Gardner L. |
Cumulative case count | 95933 | China | Unspecified | Unspecified | Unspecified | 2019-12-31 | 2020-01-28 | 2020-01-30 | Ming W, et al. |
Cumulative case count | 31200 | China | 23400 | 40400 | Unspecified | 2019-12-31 | 2020-01-29 | 2020-01-29 | Vespignani A. |
Incubation period | 4.6 | China | 3.3 | 5.7 | Unspecified | 2019-12-31 | 2020-01-25 | 2020-01-28 | Linton NM, et al. |
Incubation period | 5 | China | 4.1 | 5.8 | Unspecified | 2019-12-31 | 2020-01-25 | 2020-01-28 | Linton NM, et al. |
Time from symptom onset to hospitalization | 2.7 | China | 1.6 | 4.1 | Unspecified | 2019-12-31 | 2020-01-25 | 2020-01-28 | Linton NM, et al. |
Time from symptom onset to death | 13.8 | China | 11.8 | 16 | Unspecified | 2019-12-31 | 2020-01-25 | 2020-01-28 | Linton NM, et al. |
Time from hospitalization to death | 8.3 | China | 6.4 | 10.5 | Unspecified | 2019-12-31 | 2020-01-25 | 2020-01-28 | Linton NM, et al. |
Time from symptom onset to isolation | 2.9 | China | Unspecified | Unspecified | Unspecified | 2019-12-29 | 2020-01-23 | 2020-01-26 | Liu T, et al. |
Proportion of symptomatics that die | 0.03 | China | Unspecified | Unspecified | Unspecified | 2019-12-29 | 2020-01-23 | 2020-01-26 | Liu T, et al. |
Incubation period | 5.4 | China | 4.2 | 6.7 | Unspecified | 2019-12-10 | 2020-01-25 | 2020-01-26 | Famular, et al. |
Basic reproduction number | 2.6 | China | 1.5 | 3.5 | Unspecified | Unspecified | 2020-01-18 | 2020-01-24 | Imai N, et al. |
Date of emergence | Unspecified | China | 2020-11-19 | 2020-12-19 | Unspecified | Unspecified | Unspecified | 2020-01-23 | Neher R, et al. |
Basic reproduction number | 2.2 | China | 1.4 | 3.8 | Unspecified | 2019-11-27 | 2020-01-18 | 2020-01-23 | Riou J, et al. |
Basic reproduction number | Unspecified | China | 1.5 | 3.5 | Unspecified | 2019-11-01 | 2020-01-01 | 2020-01-23 | Neher R, et al. |
Dispersion | 0.54 | China | 0.014 | 6.95 | Unspecified | 2019-11-27 | 2020-01-18 | 2020-01-23 | Riou J, et al. |
Cumulative case count | 4000 | China | 1000 | 9700 | Unspecified | 2020-01-18 | 2020-01-18 | 2020-01-22 | Imai N, et al. |
The MIDAS Network has created a GitHub Repository for COVID-19 modeling research. The repository includes data and information, listed on this website, in computational form, mostly structured CSV files and rich metadata.
Published estimates of epidemiological characteristics, encoded by community members and approved by authors.
Listing of software created by community members, with documented metadata.
Reports, pre-prints, and peer-reviewed papers relevant to COVID-19 modeling, organized by country or by topic. All documents are also listed in a downloadable format.
Country | Collaboration Request | Collaboration Description | Contact Person | Contact Email | Date Posted |
---|---|---|---|---|---|
Bahrain | COVID-19 modeling request Bahrain | Bahrain has taken bold steps to protect its citizens and residents by rolling out a large testing effort, and preparing the health system for what can be a large outbreak given the small size of the country. At one stage a few weeks ago, it had the highest instances of COVID-19 per capita. Today, it has the second highest number of tests per capita and recovery rates globally. However, given that most instances are tied to cases that come from outside of Bahrain, it is very difficult to model the effects with local expertise. We would be extremely interested in getting evidence-based support from you and the community to feed into policy making around this important and unprecedented event. | Alya Alaali | alya.alaali@gmail.com | 2020-04-10 00:00:00 |
United States | Modeling COVID-19 and economic impact of social distancing | Our work on COVID-19 falls into 3 broad categories: 1. Basic analyses of the economic effects, including the incidence across different socio-economic and racial groups, of COVID-19 and the social distancing responses. (See an initial paper, attached, which shows that the aggregate economic effects swamp whatever is happening locally. So for states, implementing social distancing is not a primary driver of unemployment claims. Please do not redistribute it.) 2. Formal models of the spread of COVID-19 and the interconnections between the spread, social distancing responses, and economic outcomes. 3. Applying economic logic and modeling to infer true infection rates from the test results that we have. They would be excited to add subject matter expertise to all of these projects and to team up with people to collaborate with to support any of these lines of work. | Bruce Weinberg | weinberg.27@osu.edu | 2020-04-10 00:00:00 |
United States | COVID-19 intervention crowdsourced data collection | Contribute to collecting information about social distancing, using a crowdsourced platform developed by the MIDAS group at University of Virginia and Stanford University. | covid-crowd-contact@lists.stanford.edu | 2020-04-10 00:00:00 | |
United States | COVID-19 modeling and environmental geospatial factors | Jeffrey T. Morisette, PhD, Chief Scientist, National Invasive Species Council (NISC) is interested in making connections with COVID-19 transmission modelers to explore inclusion of geospatial and remote sensing data. He has a background with machine learning correlative modeling (see the Software for Assisted Habitat Modeling, note: a new version will be released shortly). These type of data and models can contribute to “natural history studies that observe disease transmission in different locations and times of year and seek correlations with environmental conditions such as temperature and humidity.” Jeff is happy to make connections with the geospatial science community, including those connected to NASA funding. | Jeffrey T. Morisette, PhD, Chief Scientist, National Invasive Species Council (NISC) | jeffrey_morisette@ios.doi.gov | 2020-04-10 00:00:00 |
India | Need for COVID-19 modeling in India | Anupama Sharma of University of Michigan is trying to provide some estimate to the India Govt for various heath-care facilities, so that they are better prepared when come out of this 21 day long lock down. He wanted to get in touch with any MIDAS members who can help us to answer (to at least a few of) the questions below for the populations US or Europe. Anybody interested can contact Anupama directly (anupamas@umich.edu). | Anupama Sharma | anupamas@umich.edu | 2020-04-03 00:00:00 |
United States | CDC COVID-19 Hospitalization Forecasting Project | Nick Reich announced the launch of the CDC COVID-19 Hospitalization Forecasting Project. In brief, with many research groups in the US working on customized models for forecasting and scenario modeling of the ongoing COVID-19 pandemic, the aim with this project is to facilitate the coordination between groups generating COVID-19 forecasts/projections and to provide curated data to decision-makers. All are welcome to participate. They will start accepting forecasts next Thursday, April 9. Early participation is encouraged, but teams may join the effort at any time. For more information, see the project GitHub. | Nick Reich | nick@schoolph.umass.edu | 2020-04-03 00:00:00 |
United States | Dr. Ashley Buchanan looking to help with COVID-19 research | Dr. Buchanan is interested in contributing to research efforts for COVID-19. Her background and training is in Biostatistics and Epidemiology from Harvard and UNC, with areas of application in HIV/AIDS and substance use. My statistical areas are causal inference and network science. She also has done some work with agent-based modeling. She would like to see if any of the teams could benefit from her collaboration and expertise | Ashley Buchanan | Buchanan@uri.edu | 2020-03-20 00:00:00 |
Professor
University of Virginia
PostDoc
Harvard University
Professor
Northeastern University
Professor
Yale University
PhD Student
Harvard University
Associate Research Scientist
Northeastern University
Associate Professor
University of Georgia
Associate Professor
University of Georgia
Professor and Head
Hong Kong University
PhD candidate
Sun Yat-Sen University
PhD Student
Tsinghua University
Professor
City University of New York
Assistant Professor
Johns Hopkins University
Associate Professor
Harvard University
Staff Scientist
U.S. Department of Health and Human Services
Professor
University of Washington
Assistant Professor
University of Louisville
Acting Assistant Professor
University of Washington
Distinguished University Professor of Health Science and Policy
University of Pittsburgh
Associate Professor
Ohio State University
Research Associate
Johns Hopkins University
PhD Student
Johns Hopkins University
Assistant Professor
Washington State University
Senior Lecturer
Imperial College London
Assistant Professor
Stanford University
Assistant Professor
Mount Holyoke College
Professor
University of Southern California
Postdoctoral Scholar
University of Antwerp
Researcher
Fondazione Edmund Mach
Postdoctoral Fellow
Centers for Disease Control and Prevention
Assistant Professor
University of Iowa
Research Scientist
Institute for Disease Modeling
Associate Professor
Emory University
Research Associate
Harvard University
Professor
University of Florida
Epidemiologist
Army Public Health Center
Sr. Systems Engineer
Catholic University of America
Research Associate Professor
University of Virginia
Professor and UNUM Chair of Excellence
University of Tennessee Chattanooga
Distingued Research Professor
University of Georgia
Professor
Hong Kong University
Associate Professor
Johns Hopkins University
Postdoctoral Researcher
University of Chicago
Assistant Professor
Zhongnan University of Economics and Law
Research Assistant Professor
University of Pittsburgh
Associate Professor
Boston University
Assistant Professor
Virginia Tech
Professor
University of Texas at Austin
Research Associate
University of Cambridge
Faculty Member
Fred Hutchinson Cancer Research Center
Professor
University of Virginia
Senior Research Scientist
French National Institute for Sustainable Development
Professor
Harvard University
Associate Professor
University of Michigan
Professor of Vaccine Epidemiology
London School of Hygiene & Tropical Medicine
Associate Research Scientist
Northeastern University
Epidemiologist
U.S. Department of Health and Human Services
Assistant Professor
Harvard University
Assistant Professor
University of Maryland
Assistant Professor
Columbia University
Biologist
U.S. Department of Health and Human Services
Post Doctoral Fellow
Emory University
Department Head
Imperial College London
Associate Professor
University of Massachusetts Amherst
PhD Candidate
University of Georgia
PostDoc
Harvard University
Staff Scientist
Fred Hutchinson Cancer Research Center
ORISE Fellow
U.S. Department of Health and Human Services
PhD Student
University of Missouri
Modeling Unit Lead
U.S. Department of Health and Human Services
Research Associate
Harvard University
Professor
Carnegie Mellon University
Associate Professor
Harvard University
Research Associate
Imperial College London
PhD Student
Harvard University
PhD Student
Princeton University
Deputy Group Leader
Los Alamos National Laboratory
Associate Professor
University of Chicago
PhD Student
University of California San Francisco
PostDoc
University of California San Francisco
Associate Professor
University of Washington
Head of Structure
Institut Pasteur
Associate Professor
University of Michigan
Research Scientist
University of Virginia
Professor and Deputy Director
University of Virginia
Professor of Infectious Disease Dynamics
Imperial College London
Senior Programming Analyst
Temple University
Research Assistant Professor
Hong Kong University
PostDoc
Boston University
PhD Candidate
University of Washington
Professor
University of California San Francisco
Associate Member
Fred Hutchinson Cancer Research Center
Postdoctoral Research Fellow
Harvard University
Professor of Infectious Disease Modelling
London School of Hygiene & Tropical Medicine
Assistant Professor
Columbia University
Research Associate
Boston Children’s Hospital
Associate Professor
Harvard University
PostDoc
Emory University
Associate Professor
University of Florida
Doctoral Candidate
University of Maryland
MIDAS Coordination Center
University of Pittsburgh
A737 Public Health
130 DeSoto Street
Pittsburgh PA 15261